Executive Director, Global Publications, Scientific Communications, and Medical Information

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases.

Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.

Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas’ earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcγRIIb monoclonal antibody.

We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation – TRUE Innovation!

Position Summary:

Zenas Bio Pharma is seeking a strategic, visionary, and execution-oriented leader for the role of Executive Director, Global Publications, Scientific Communications, and Medical Information. In this leadership position within Global Medical Affairs, the individual will establish and drive the overarching scientific communication strategy, publication planning, and medical information infrastructure supporting the immunology pipeline, including lead programs such as obexelimab and orelabrutinib across indications including IgG4-Related Disease (IgG4-RD), Systemic Lupus Erythematosus (SLE), and Multiple Sclerosis (MS).This

role serves as a core medical leadership pillar responsible for translating complex clinical and translational science into transparent, compliant, and impactful scientific narratives for healthcare professionals, researchers, regulatory authorities, and patients. The individual will build and scale a high-performing team and agency ecosystem to support upcoming pivotal data disclosures, regulatory filings, and potential commercial launches.

Key Responsibilities:

Strategic Scientific Communications & Narrative Generation Architect and operationalize global strategic scientific communication platforms (SSCP) and core scientific statements across all development and lifecycle stages.

Partner cross-functionally with Clinical Development, Translational Medicine, Regulatory Affairs, and Commercial Strategy to ensure integrated, scientifically rigorous narratives aligned with clinical value propositions.

Lead the creation and lifecycle maintenance of internal medical education assets,…